Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models (Q40071705)

17 September 2017

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models (English)

1 reference

17 September 2017

2

Rama Rao Amara

1 reference

17 September 2017

Lynette Siv Chea

1

1 reference

17 September 2017

25 August 2017

1 reference

Expert Review of Vaccines

17 September 2017

1 reference

17 September 2017

16

1 reference

17 September 2017

10

1 reference

17 September 2017

973-985

1 reference

The origin and diversity of the HIV-1 pandemic

17 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Evolutionary and immunological implications of contemporary HIV-1 variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

HIV-1 vaccines: challenges and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Which Antibody Functions are Important for an HIV Vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

A Blueprint for HIV Vaccine Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

CD4 T follicular helper cell dynamics during SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Technologies for enhanced efficacy of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Synthetic DNA vaccine strategies against persistent viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Vaccinia virus: a tool for research and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Smallpox vaccines for biodefense

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Recombinant MVA vaccines: dispelling the myths

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Local control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Humoral immunity to HIV-1: neutralization and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Non-neutralizing antibodies in prevention of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Follicular helper CD4 T cells (TFH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

Prospects for a globally effective HIV-1 vaccine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6120759

Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6120759

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6120759

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6120759

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice

4 November 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1371594

HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28838267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28838267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28838267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/14760584.2017.1371594

1 reference

17 September 2017

0 references

1 reference

PubMed ID

28838267